Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2010

View Archived Issues

Phase I and preclinical data presented on PD-0332991 in multiple myeloma

GlaxoSmithKline discloses new monoamine reuptake inhibitors

New meningitis vaccine MenAfriVac is introduced in Africa

Kinase inhibitors from Bayer show oncolytic activity alone and in combination

Nerviano discloses promising preclinical/clinical data on new oncolytic compounds

EyeGene's EGT-022 shows therapeutic potential in retinopathy model

Truvada prevents HIV infection in men who have sex with men

Intercell discontinues development of vaccine patch for traveler's diarrhea

Eisai launches anticancer agent Treakisym in Japan

Merck & Co. claims new inhibitors of kinesin-like protein KIF11

Novel inhibitors of M-phase inducer phosphatase 3 claimed

Forest Labs and Gruenenthal to develop new analgesics GRT-6005 and GRT-6006

Katholieke Universiteit Leuven claims new agents for treatment of HIV infections

Spherix presents data from phase II trial of D-tagatose

Talecris Biotherapeutics begins phase II trial of Prolastin-C

New modulators discovered of transient receptor potential TRPM8 channel

FDA approves clinical development plan for Menerba

Ancora Pharma receives federal grants to develop vaccines for malaria and S. aureus infection

GeoVax reports phase IIa data on HIV vaccines pGA2/JS7 and MVA-HIV62

Arena Pharma begins phase I trial of APD-811 for pulmonary arterial hypertension

Pfizer withdraws Thelin from market and halts clinical trials

Zealand Pharma receives milestone payment from Helsinn Healthcare regarding ZP-1846

SI-6603 shows promise to treat lumbar disc herniation in Seikagaku's phase II/III trial

Capstone releases phase IIa data on AZX-100 for treatment of keloid and surgical scarring

Infinity Pharma and Mundipharma extend alliance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...